CIPO Patents = 1

EPO Patents = 3

Forward Citations = 45

Loading Chart...

6 inventors (with patents filed for the assignee):

Thomas Kirkegaard Jensen (4 out of 13 patents)

Marja Helena Jaattela (3 out of 7 patents)

Anders Mørkeberg Hinsby (1 out of 5 patents)

4. Linda Greensmith (1 out of 1 patent)

5. Geoffrey Burnstock (1 out of 1 patent)

6. Rudolf Urbanics (1 out of 1 patent)

5 patents: Sort by Forward Citations

1. 9884058 - Use of Hsp70 as a regulator of enzymatic activity (2018-02-06),

2. 9662375 - Methods for increasing intracellular activity of Hsp70 (2017-05-30),

3. 9289472 - Use of HSP70 as a regulator of enzymatic activity (2016-03-22),

4. 8962604 - Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases (2015-02-24),

5. 8540985 - Use of Hsp70 as a regulator of enzymatic activity (2013-09-24),

Orphazyme Aps is a biopharmaceutical company dedicated to developing novel therapies for patients with rare neurological diseases. Their lead candidate, Arimoclomol, is being investigated for the treatment of neurodegenerative disorders such as Niemann-Pick disease type C and sporadic Inclusion Body Myositis. Orphazyme's mission is to bring hope to patients and their families by advancing innovative treatments that address unmet medical needs.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 13 2026

5 Patents

#1 in København N

#464 in Denmark

København N, Denmark

Orphazyme Aps

Forward Citations = 45

6 inventors:

Thomas Kirkegaard Jensen (4 out of 13 patents)

Marja Helena Jaattela (3 out of 7 patents)

Anders Mørkeberg Hinsby (1 out of 5 patents)

4. Linda Greensmith (1 out of 1 patent)

5. Geoffrey Burnstock (1 out of 1 patent)

Please report any incorrect information to support@idiyas.com

1 patent (CIPO):

Please report any incorrect information to support@idiyas.com

3 patents (EPO):

Please report any incorrect information to support@idiyas.com